Note: Ingredients listed on restricted chemical lists
EC/CAS
203-313-2/105-60-2
Name of the chemical
ε-caprolactam
Concentration
>=60-<70 >=10-<15
EC/CAS
203-234-3/104-76-7
Name of the chemical
2-ethyl-1-hexanol
Concentration
>=5-<10
EC/CAS
203-312-7/105-59-9
Name of the chemical
2,2'-methyliminodiethanol
Concentration
>=1-<5
EC/CAS
200-338-0/57-55-6
Name of the chemical
1,2-propanediol
Concentration
>=10-<15
General Information
Revision date
2022-12-21
Product name
ARMOFLOTE 940
1.2.1 Relevant identified uses
For research use only
Icons in SDS
Company Information
company name
Nouryon Surface Chemistry AB
e-mail address of the competent person responsible for the Safety Data Sheet
Regulatory.Affairs@nouryon.com
GHS Information
Signal word
Warning
Hazard Codes
Hazard statements (CLP)
H315, H319, H411
Hazard statements
Code
Statements
H315
Causes skin irritation
Section 2
SECTION 2: Hazards identification
2.1 Classification of the substance or mixture
Classification
Signal word
Warning
Hazard statements
H315 Causes skin irritation. H319 Causes serious eye irritation. H411 Toxic to aquatic life with long lasting effects.
Prevention
P264 Wash skin thoroughly after handling. P273 Avoid release to the environment. P280 Wear protective gloves/ eye protection/ face protection.
Response
P337 + P313 If eye irritation persists: Get medical advice/ attention. P391 Collect spillage.
Disposal
P501 Dispose of contents/ container to an approved waste disposal plant.
2.3 Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
ECOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
TOXICOLOGICAL INFORMATION
The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.
